Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1

Interventions

Paclitaxel 6Taxes 5Carboplatin 5Immunoglobulin G 2Disulfides 2Bevacizumab 2sargramostim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1belinostat 1adavosertib 1VTX-2337 1Surgical Procedures, Operative 1Metformin 1Immunologic Techniques 1Imatinib Mesylate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1Drug Therapy 1Cytoreduction Surgical Procedures 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brenner Tumor × elesclomol × Clear all
NCT00888615 2021-10-20

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
58 enrolled 13 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡